The latest to join the charge of the biotech buyout brigade are Merrimack Pharmaceuticals and Cubist Therapeutics. Merrimack has acquired Hermes Biosciences in a technology-oriented acquisition and Cubist has acquired Calixa Therapeutics to add a promising mid-stage antibiotic to its pipeline.